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Mechanical and oral antibiotic bowel preparation versus 
no bowel preparation for elective colectomy (MOBILE): 
a multicentre, randomised, parallel, single-blinded trial
Laura Koskenvuo, Taru Lehtonen, Selja Koskensalo, Suvi Rasilainen, Kai Klintrup, Anu Ehrlich, Tarja Pinta, Tom Scheinin, Ville Sallinen
Summary
Background Decreased surgical site infections (SSIs) and morbidity have been reported with mechanical and oral 
antibiotic bowel preparation (MOABP) compared with no bowel preparation (NBP) in colonic surgery. Several 
societies have recommended routine use of MOABP in patients undergoing colon resection on the basis of these 
data. Our aim was to investigate this recommendation in a prospective randomised context.
Methods In this multicentre, parallel, single-blinded trial, patients undergoing colon resection were randomly assigned 
(1:1) to either MOABP or NBP in four hospitals in Finland, using a web-based randomisation technique. Randomly 
varying block sizes (four, six, and eight) were used for randomisation, and stratification was done according to centre. 
The recruiters, treating physicians, operating surgeons, data collectors, and analysts were masked to the allocated 
treatment. Key exclusion criteria were need for emergency surgery; bowel obstruction; colonoscopy planned during 
surgery; allergy to polyethylene glycol, neomycin, or metronidazole; and age younger than 18 years or older than 
95 years. Study nurses opened numbered opaque envelopes containing the patient allocated group, and instructed the 
patients according to the allocation group to either prepare the bowel, or not prepare the bowel. Patients allocated to 
MOABP prepared their bowel by drinking 2 L of polyethylene glycol and 1 L of clear fluid before 6 pm on the day before 
surgery and took 2 g of neomycin orally at 7 pm and 2 g of metronidazole orally at 11 pm the day before surgery. The 
primary outcome was SSI within 30 days after surgery, analysed in the modified intention-to-treat population 
(all patients who were randomly allocated to and underwent elective colon resection with an anastomosis) along with 
safety analyses. The trial is registered with ClinicalTrials.gov, NCT02652637, and EudraCT, 2015–004559–38, and is 
closed to new participants.
Findings Between March 17, 2016, and Aug 20, 2018, 738 patients were assessed for eligibility. Of the 417 patients who 
were randomised (209 to MOABP and 208 to NBP), 13 in the MOABP group and eight in the NBP were excluded 
before undergoing colonic resection; therefore, the modified intention-to-treat analysis included 396 patients (196 for 
MOABP and 200 for NBP). SSI was detected in 13 (7%) of 196 patients randomised to MOABP, and in 21 (11%) of 
200 patients randomised to NBP (odds ratio 1·65, 95% CI 0·80–3·40; p=0·17). Anastomotic dehiscence was reported 
in 7 (4%) of 196 patients in the MOABP group and in 8 (4%) of 200 in the NBP group, and reoperations were 
necessary in 16 (8%) of 196 compared with 13 (7%) of 200 patients. Two patients died in the NBP group and none in 
the MOABP group within 30 days.
Interpretation MOABP does not reduce SSIs or the overall morbidity of colon surgery compared with NBP. We 
therefore propose that the current recommendations of using MOABP for colectomies to reduce SSIs or morbidity 
should be reconsidered.
Funding Vatsatautien Tutkimussäätiö Foundation, Mary and Georg Ehrnrooth’s Foundation, and Helsinki University 
Hospital research funds.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Although postoperative recovery of colon surgery has 
improved over the past few decades because of minimally 
invasive techniques and enhanced recovery after surgery 
(ERAS) protocols,1,2 colon surgery is still associated 
with morbidity. The majority of morbidities arise from 
surgical site infections (SSIs),3–4 which can vary from 
superficial wound infections to life-threatening colonic 
anastomotic leakage. Mechanical bowel preparation was 
once routinely used and thought to improve outcomes; 
however, it has not been recommended for nearly 
two decades because evidence from randomised trials, 
and later meta-analyses and a Cochrane review, indicated 
no benefit over no bowel preparation (NBP) in elective 
colon surgery.5–8
Results from several large retrospective series stemming 
from the American College of Surgeons National Surgical 
Quality Improvement Program (ASC NSQIP) have 
challenged the dogma surrounding NBP and suggested 
that mechanical and oral antibiotic bowel preparation 
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(MOABP) decreases the rate of SSIs and overall compli-
cations compared with NBP.9–16 Four large societies 
have changed their recommendations on the basis of 
these large retrospective trials. The American Society of 
Colon and Rectal Surgeons, the Society of American 
Gastrointestinal and Endoscopic Surgeons, the American 
Society for Enhanced Recovery, and the Perioperative 
Quality Initiative all now recommend MOABP over 
NPB.17–19 Notably, no prospective randomised trials have 
yet compared MOABP with the current standard of care, 
which is NBP. A meta-analysis20 also emphasised the 
scarcity of literature on the comparison between MOABP 
and NBP. Although many randomised controlled trials 
have compared MOABP with mechanical bowel prepara-
tion, and show benefit in favour of MOABP,20–23 the results 
cannot be extrapolated to the NBP strategy. Mechanical 
bowel preparation could increase the prevalence of SSIs, 
for reasons that remain unknown.24
Because of scarcity of evidence and controversy 
regarding the benefits of MOABP, we did a study to 
compare MOABP with NBP for elective colectomy (the 
MOBILE trial). Our hypothesis, based on retrospective 
series, was that MOABP reduces the prevalence of 
SSIs and overall complications following colon surgery. 
We report here the primary and secondary outcomes; 
tertiary and long-term survival outcomes will be reported 
at the 5-year follow-up.
Methods
Study design
The MOBILE trial was a national, multicentre, single-
blinded, parallel group, individually randomised superi-
ority trial comparing MOABP with NBP in patients 
undergoing elective colon surgery. The trial was done in 
four Finnish hospitals: two university hospitals (Helsinki 
University Hospital and Oulu University hospital) and 
two community (central) hospitals (Central Finland 
Central Hospital and Seinäjoki Central Hospital). All 
participating hospitals are government funded and 
provide care to all patients within their catchment 
area. Colonic surgery is extremely rare in private hospitals 
in Finland. The research plan was approved by the 
Finnish National Committee on Medical Research Ethics 
and Finnish Medicines Agency. The research plan was 
Research in context
Evidence before this study
Bowel preparation for elective colectomies has not been routinely 
used during the past few decades. Results of several large 
retrospective series stemming from the American College of 
Surgeons National Surgical Quality Improvement Program have 
suggested that mechanical and oral antibiotic bowel preparation 
(MOABP) decreases the rate of surgical site infections (SSIs) and 
overall complications compared with no bowel preparation 
(NBP). Before initiation of the study trial in November, 2015,  
we searched PubMed and ClinicalTrials.gov for randomised 
clinical trials published in English, between January, 1980, 
and November, 2015, that had compared MOABP with NBP using 
the search terms “bowel preparation and colon”, “colectomy”, 
or “colorectal”. We did not find any randomised controlled trials.
Added value of this study
This is, to our knowledge, the first randomised trial comparing 
MOABP with NBP before colectomy. The primary outcome, SSI, 
was similar between the MOABP and NBP groups (7% vs 11%). 
Furthermore, the total burden of complications, measured using 
Comprehensive Complication Index, did not differ between the 
groups (10·0 points in the MOABP group, 9·0 points in the 
NBP group) and anastomotic dehiscence (4% vs 4%), 
reoperations (8% vs 7%), or hospital stay (5·4 days for MOABP 
and 5·3 days for NBP) were also similar between the groups.
Implications of all the available evidence
Our study proposes to reconsider the current recommendations 
of using MOABP for colectomies to reduce SSIs or morbidity.
Figure: Trial profile
*One patient required emergency surgery and three patients withdrew consent. †One patient underwent 
operation in another hospital and one patient withdrew consent. ‡Eight patients only partially prepared their 
bowel with polyethylene glycol, one took antibiotics before bowel preparation, three only partially received 
antibiotics, and one did not take antibiotics. §Two patients prepared bowel with polyethylene glycol. 
736 patients assessed for eligibility
417 randomly assigned
209 allocated to mechanical bowel preparation 
 combined with per oral antibiotics
196 analysed in modified intention-to-treat analysis
319 excluded
 229 met exclusion criteria
 162 required bowel preparation 
 27 needed emergency surgery
 25 with bowel obstruction
 3 allergic to intervention medicine
 12 with colonoscopy planned during surgery
 86 declined to participate
 4 were participating in other trials
13 excluded
 4 did not have surgery
 5 did not have anastomosis
 4 cancelled participation*
196 underwent colonic resection
 172 received allocated intervention
 13 partially received allocated intervention‡
 7 did not receive allocated intervention
 4 with data from intervention missing
200 analysed in modified intention-to-treat analysis
200 underwent colonic resection
 198 received allocated intervention
 2 did not receive allocated intervention§
8 excluded
 3 did not have surgery
 3 did not have anastomosis
 2 cancelled participation†
208 allocated to no bowel preparation
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further approved by the local ethics committee of Helsinki 
University Hospital and by each participating centre’s 
institutional review board (Helsinki University Hospital, 
Oulu University Hospital, Central Finland Central 
Hospital, and Seinäjoki Central Hospital).
Participants
Patients who were scheduled for colon resection in 
participating centres were eligible for inclusion. Exclusion 
criteria were as follows: need for emergency surgery; 
bowel obstruction; colonoscopy planned to be under-
taken during surgery; other indications for mechanical 
preparation or contraindications; allergy to drugs used in 
the trial (polyethylene glycol, neomycin, metronidazole); 
and age younger than 18 years or older than 95 years. 
No restrictions were applied on indication for colon 
resection. Both benign and malignant indications were 
eligible, as were both laparoscopic and open procedures. 
Patients provided written informed consent.
Randomisation and masking
Patients were randomly allocated in a 1:1 ratio to either 
MOABP or NBP. The randomisation sequence was gen-
erated using a web-based service. A block random isation 
with randomly varying block size (four, six, and eight) was 
stratified according to centre. The web-based random-
isation sequence was concealed in opaque numbered 
envelopes, which were opened in numerical order.
 The recruiters, treating physicians, operating surgeons, 
data collec tors, analysts, and patients were unaware of 
the random isation sequence. After patients who met 
inclusion and exclusion criteria gave consent, the study 
nurse enrolled the patients to the trial, took them to 
another room, opened the numbered opaque envelope 
containing the allocated group, and instructed the 
patients according to the allocation group to either 
prepare the bowel, or not prepare the bowel. The study 
nurse also gave the medications and sub stances for 
mechanical bowel preparation, and then had no further 
role in the trial. The recruiters, treating physicians, 
operating surgeons, data collectors, and analysts were 
masked to the allocated treatment. Because patients 
could not be masked to allocation to mechanical bowel 
preparation, patients were aware of their intervention. 
After all the data were collected, the two groups were 
named as A and B. Primary and secondary outcomes 
were analysed without knowing the group names. Full 
blinding was removed only after the analyses for primary 
and secondary outcomes were done. Incidents of 
ineffective blinding (eg, patient telling the treating 
physicians about the bowel preparation) were recorded.
Procedures
Patients allocated to MOABP were instructed by the 
study nurse to prepare their bowel mechanically by 
drinking 2 L of polyethylene glycol (Moviprep Norgine PV; 
Amsterdam, Netherlands) and 1 L of clear fluid before 
Mechanical and oral 
antibiotic bowel 
preparation (n=196)
No bowel preparation 
(n=200)
Demographics
Age, years 69·9 (61·1–75·2) 70·3 (61·0–76·0)
Sex
Female 91 (46%) 104 (52%)
Male 105 (54%) 96 (48%)
Body-mass index, kg/m² 27·0 (4·3)* 27·2 (5·2)
Albumin concentration, g/L 36·4 (5·2)† 35·7 (4·6)‡
Smokers 19/190 (10%)§ 16/191 (8%)¶
ASA physical status score
1 20 (10%) 23 (12%)
2 77 (39%) 85 (43%)
3 88 (45%) 79 (40%) 
4 11 (6%) 13 (7%)
Comorbidities
Myocardial infarction 12 (6%) 7 (4%)
Congestive heart failure 14 (7%) 11 (6%)
Coronary disease (not infarction) 27 (14%) 19 (10%)
Hypertension 87 (44%) 85 (43%)
Atrial fibrillation 25 (13%) 29 (15%)
Peripheral vascular disease 14 (7%) 9 (5%)
Cerebrovascular disease 14 (7%) 10 (5%)
Hemiplegia 1 (1%) 1 (1%)
Dementia 1 (1%) 3 (2%)
COPD or asthma 33 (17%) 28 (14%)
Connective tissue disease 7 (4%) 5 (3%)
Liver disease
Mild 2 (1%) 3 (2%)
Moderate or severe 2 (1%) 1 (1%)
Diabetes
Without complications 33 (17%) 42 (21%)
With complications 5 (3%) 1 (1%)
Kidney disease (moderate or severe) 7 (4%) 8 (4%)
Cancer 145 (74%) 136 (68%)
Metastatic malignancy 8 (4%) 20 (10%)
No comorbidities 21 (11%) 22 (11%)
Charlson Comorbidity Index
Mild (0–2) 117 (60%) 119 (60%)
Moderate (3–4) 52 (27%) 51 (26%)
Severe (≥5) 27 (14%) 30 (15%)
Mean score 2·5 (1·8) 2·7 (2·1)
Medication
Aspirin 29 (15%) 31 (16%)
Clopidogrel 9 (5%) 4 (2%)
Varfarin 15 (8%) 20 (10%)
Low molecular weight heparin 9 (5%) 4 (2%)
Direct oral anticoagulant 7 (4%) 4 (2%)
Two or more medications that affect thrombosis 
(anticoagulant or antithrombotic)
2 (1%) 4 (2%)
Corticosteroid or immunosuppressive medication 8 (4%) 6 (3%)
No high-risk medication 117 (60%) 127 (64%)
(Table 1 continues on next page)
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6 pm in the evening the day before the surgery, and 
take 2 g of neomycin orally at 7 pm and 2 g of 
metronidazole orally at 11 pm in the evening the day 
before the surgery. A similar per oral antibiotic regimen 
has been used in earlier trials comparing MOABP 
with mechanical bowel preparation.25,26 Patients allo-
cated to NBP were instructed to not prepare the bowel. 
The receipt of the allocated intervention was controlled 
by a nurse asking the patients on the morning of the 
surgery whether they had acted as instructed by 
the allocation. This infor mation was also concealed 
from treating physicians and surgeons, data collectors, 
and data analysts, until the primary and secondary 
outcomes were analysed. All patients followed the 
ERAS protocol.27 Prophylactic intravenous antibiotics 
(cefuroxime 1500 mg and metronidazole 500 mg) were 
given to all patients at the start of anaesthesia before 
skin incision. The prophylactic intravenous antibiotics 
were re-administered if the surgery lasted longer than 
3 h from the first antibiotic dose, or if blood loss 
exceeded 1·5 L. Surgical skin preparation involved 
shaving the hair from the operation area in the morning 
of the operation day. Just before skin incision, the 
area was then washed three times with denatured 
80% alcohol and left to dry.
The patients were contacted 30 days after the operation 
either by visit to the outpatient clinic or by phone, and at 
6 months by a follow-up visit at the outpatient clinic. 
Patients were asked about any complications that had 
occurred after discharge, and clinical examination was 
carried out during visits to the outpatient clinic.
Outcomes
The primary outcome was SSI within 30 days after sur gery. 
SSI was defined using Center for Disease Control and 
Prevention criteria28 and was subcategorised as super-
ficial incisional SSI, deep incisional SSI, or organ space 
SSI. Secondary outcome measures were Compre hensive 
Complication Index (CCI) score within 30 days after 
surgery, in which all the complications were recorded 
by Clavien-Dindo (CD) classification, weighted (CD 1=300, 
CD2=1750, CD3a=2750, CD3b=4550, CD4a=7200, 
CD4b=8550) and summed together (CCI=Ö(wC1+wC2…
+wCx) / 2, death equals CCI=100);26 anastomotic dehiscence 
within 30 days after surgery, including (1) anastomotic 
dehiscence detected endoscopically or radiologically, but 
requiring no therapeutic intervention, (2) dehiscence 
requiring thera peutic intervention, but no laparotomy, 
and (3) dehis cence requiring re-laparotomy;29 reoperation 
within 30 days after surgery; readmission within 30 days 
after surgery; length of hospital stay (assessed at the time 
of dis charge); mortality within 30 days and 90 days after 
surgery; adverse effects of antibiotics (diarrhoea, clos-
tridium) within 30 days after surgery; and prevalence of 
adjuvant therapy (number of patients receiving adjuvant 
therapy divided by number of patients needing adjuvant 
therapy) assessed at 6 months after surgery.
Outcome measures were assessed during the hospital 
stay and at 1-month clinical follow-up visit at the 
outpatient clinic. A regular colorectal cancer follow-up 
was scheduled for patients with colorectal cancer. 90-day 
Mechanical and oral 
antibiotic bowel 
preparation (n=196)
No bowel preparation 
(n=200)
(Continued from previous page)
Previous operations 
Previous abdominal or inguinal operation 96 (49%) 102 (51%)
Data are n (%), n/N (%), median (IQR), or mean (SD). ASA=American Association of Anesthesiologists. COPD=chronic 
obstructive pulmonary disorder. Patients with missing data for each variable were not included in calculations. 
*Two patients had missing data. †Seven patients had missing data. ‡Nine patients had missing data. §Six patients had 
missing data. ¶Nine patients had missing data.
Table 1: Baseline characteristics
Mechanical and oral 
antibiotic bowel 
preparation (n=196)
No bowel 
preparation 
(n=200)
Indication for surgery
Colorectal cancer 152 (78%) 153 (77%)
Colorectal adenoma or other 
benign tumours
19 (10%) 19 (10%)
Diverticulosis 23 (12%) 28 (14%)
Previous volvulus 2 (1%) 0
Resection site
Right side 108 (55%) 113 (57%)
Left side 82 (42%) 80 (40%)
Colectomy 6 (3%) 7 (4%)
Resection type
Ileocecal 3 (2%) 2 (1%)
Right hemicolectomy 103 (53%) 109 (55%)
Transverse colon resection 5 (3%) 1 (1%)
Left hemicolectomy 38 (19%) 38 (19%)
Sigmoid resection 37 (19%) 35 (18%)
Anterior rectal resection 4 (2%) 6 (3%)
Subtotal colectomy 6 (3%) 7 (4%)
Other 0 2 (1%)*
Surgical approach
Open 26 (13%) 24 (12%)
Laparoscopic 151 (77%) 159 (80%)
Laparoscopy converted to open 19 (10%) 17 (9%)
Operation details
Preoperative intravenous 
antibiotic time, min before 
incision
43·0 (22·9)† 42·1 (27·4)‡
Duration of operation, min 162·7 (61·8)§ 159·7 (52·9)
Intraoperative blood loss, mL 121·2 (185·2)¶ 116·1 (121·5)||
No significant differences were identified between the treatment groups in any 
operative variables. Data are n (%), or mean (SD). Patients with missing data for 
each variable were not included in calculations. *One cecal resection and 
one reversal of Hartmann’s procedure. †Three patients had missing data. 
‡Two patients had missing data. §One patient had missing data. ¶Two patients 
had missing data. ||One patient had missing data.
Table 2: Operative details
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mortality was assessed during these follow-up visits, or, 
if no visits took place, directly from electronic patient 
records, which automatically update from the Population 
Register Centre.
Tertiary outcomes were 5-year overall survival, 5-year 
disease-specific survival, and 5-year recurrence-free 
survival, and applied only to patients with cancer. These 
outcomes will be reported when 5-year follow-up data are 
available. Data were collected by using paper case report 
forms.
Statistical analysis
Retrospective studies have shown that the prevalence of 
SSIs varied from 3·2% to 8·6% in patients undergoing 
MOABP and from 9·0% to 16·8% in patients with 
NBP.9–12 On the basis of these figures, we aimed to show 
an 8% absolute difference in occurrence of SSIs, and 
estimated that SSIs would occur in 5% of patients 
undergoing MOABP, and 13% of patients with NBP. 
With a power of 80% and significance at 5%, 396 patients 
would be needed to show this difference. The sample 
size was adjusted for a possible 5% loss, yielding a final 
sample size of 415 patients.
Categorical variables (SSI, anastomotic dehiscence, 
reoperation, readmission, adverse effect of antibiotics, 
given adjuvants) were compared using χ² test, or Fisher’s 
exact test if expected cases in one cell were fewer than 
five. Effect size for categorical variables was estimated 
using odds ratios (ORs) with 95% CIs. For instances 
in which zeros caused problems with compu tation of 
the OR, 0·5 was added to all values. Continuous vari-
ables with normal distribution (mean CCI, mean length 
of hospital stay) are reported as means with SD and were 
compared using Student’s t test. Effect size for such 
variables was esti mated by reporting difference of means 
with 95% CIs. Continuous variables with non-normal 
distribution are reported as medians with IQRs and 
compared using the Mann–Whitney U test.
Statistical analyses were performed using SPSS Statistics 
25 software. Statistical significance was set at a two-sided α 
of 0·05. Patients with missing values were excluded from 
analyses of that particular variable, and missing values 
were not imputed. Number of patients with missing 
values, if any, are stated within the tables or in the text 
when reporting the variable. Outcomes were analysed 
using the modified intention-to-treat principle, which 
included all patients who were randomly allocated to and 
underwent elective colon resection with an anastomosis 
(patients who were not operated on, those who were 
operated emergently while waiting for scheduled elective 
operation in whom anastomosis was not done, or those 
who underwent only explorative laparoscopy or laparotomy 
were excluded for all analyses). Patients who withdrew 
consent were analysed up to the point of withdrawal. No 
changes in the study protocol occurred after the trial 
started. The trial is registered with ClinicalTrials.gov 
(NCT02652637) and EudraCT (2015–004559–38).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author (LK) had 
full access to all the data in the study. LK and VS had final 
responsibility for the decision to submit for publication.
Results
Between March 17, 2016, and Aug 20, 2018, 736 patients 
were assessed for eligibility in four Finnish hospitals 
(figure; appendix). 229 patients met an exclusion 
criterion, 86 de clined to participate, and four patients 
were participating in other trials. 417 patients were 
enrolled and randomly allocated to treatment. Of the 
randomised patients, 21 were excluded from the analyses 
after randomisation, leaving 396 patients in the final 
modified intention-to-treat analyses (196 patients for 
MOABP vs 200 patients for NBP).
Patient baseline characteristics were similar between 
the two groups (table 1), as were perioperative details 
(table 2). Preoperative prophylactic intravenous anti bio tic 
times were similar in both groups (table 2). The operation 
time was 180–240 min in 81 patients (37 in the MOABP 
group and 44 in the NBP group), and 47 (24 in the MOABP 
Mechanical and 
oral antibiotic 
bowel preparation 
(n=196)
No bowel 
preparation 
(n=200)
Effect size (95% CI) or 
mean difference 
(95% CI)*
p value
Surgical site infection† 13 (7%) 21 (11%) 1·65 (0·80 to 3·40) 0·17
Superficial 1 (1%) 5 (3%) ·· ··
Deep 3 (2%) 4 (2%) ·· ··
Organ site infection 9 (5%) 12 (6%) ·· ··
Mean Comprehensive 
Complication Index
10·0 (13·2) 9·0 (15·5) 1·08 (–1·77 to 3·93) 0·46
Anastomotic dehiscence 7 (4%) 8 (4%) 1·13 (0·40 to 3·16) 0·82
Reoperation 16 (8%) 13 (7%) 0·78 (0·37 to 1·67) 0·53
Readmission 12/193 (6%)‡ 13/196 (7%)§ 1·07 (0·47 to 2·40) 0·88
Mean length of hospital stay, 
days
5·4 (4·7) 5·3 (4·4) 0·07 (–0·83 to 0·97) 0·87
Mortality at 30 days 0 2 (1%) 4·95 (0·24 to 103·77) 0·50
Mortality at 90 days 0 2 (1%) 4·95 (0·24 to 103·77) 0·50
Adverse effect of antibiotics 12 (6%) 13 (7%) 1·07 (0·47 to 2·40) 0·88
Diarrhoea 10 (5%) 11 (6%) ·· ··
Clostridium spp infection 0 1 (1%) ·· ··
Allergic reaction 0 1 (1%) ·· ··
Candida spp infection 2 (1%) 0 ·· ··
Adjuvant treatment given 
(out of number who needed 
treatment)
60/72 (83%) 74/87 (85%) 0·88 (0·37 to 2·07) 0·77
Data are n (%), n/N (%), or mean (SD) unless otherwise specified. Patients with missing data for each variable were not 
included in calculations. *For means, difference is given with 95% CI; for binary outcomes, odds ratio is given with 
95% CI. †Only the most severe type of surgical site infection is reported here; table 4 contains a complete list of all 
complications (including multiple types of surgical site infections). ‡Three patients had missing data. §Four patients had 
missing data.
Table 3: Primary and secondary outcomes
For more on Population 
Register Centre see https://vrk.
fi/en/frontpage
See Online for appendix
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group and 23 in the NBP group) of these 81 patients were 
given another dose of prophylactic intravenous antibiotics. 
The operation time exceeded 240 minutes in 37 patients 
(21 in the MOABP group and 16 in the NBP group), and 
15 (nine in the MOABP group and six in the NBP group) 
of these 37 patients were given another dose of 
prophylactic intravenous antibiotics. Blood loss did not 
exceed 1·5 L in any of the patients. Masking was reported 
to have been unsuccessful in one patient in the MOABP 
group and none in the NBP group.
SSI was detected in 13 (7%) of 196 patients in the 
MOABP group and in 21 (11%) of 200 in the NBP group 
(OR 1·65 [95% CI 0·80 to 3·40], p=0·17; absolute difference 
3·9% [95% CI –1·6 to 9·4]; table 3). The subgroups of 
SSIs were similarly distributed in both groups (table 3). 
CCI was similar between the groups (table 3), and 
anastomotic dehiscence was detected in seven (4%, all 
Class C) of patients in the MOABP group versus eight 
patients (4%, one Class A, seven Class C) in the NBP group 
(table 3). Reoperation was required in 16 (8%) patients in 
the MOABP group versus 13 (7%) patients in the NBP 
group (table 3). Reoperation was because of anastomotic 
dehis cence in seven patients, suspected anastomotic 
dehiscence in two patients, fascial rupture in three patients, 
occlusion in one patient, intra-abdominal bleeding in two 
patients, and ureter lesion in one patient in the MOABP 
group; and because of anastomotic leakage in seven 
patients, intra-abdominal bleeding in one patient, fascial 
rupture in three patients, occlusion in one patient, and 
intestinal necrosis in one patient in the NBP group. 
12 (6%) patients were readmitted to hospital in the MOABP 
group because of abdominal pain (three patients), SSI 
(one patient), ileus (three patients), intraluminal bleeding 
(one patient), fever (one patient), and urinary tract 
infection and retention (three patients). 13 (7%) patients 
were readmitted to hospital in the NBP group for 
abdominal pain (three patients), SSI (five patients), ileus 
(two patients), intraluminal bleeding (two patients), and 
diarrhoea (one patient). One patient in both groups was 
still in hospital after 30 postoperative days. Mean length of 
hos pital stay was similar in both groups (table 3). There 
were no deaths within 90 days in the MOABP group. 
Two patients died within 90 days in the NBP group (both 
within 30 days). One of them (age 83 years, American 
Association of Anestheologists [ASA] class 4, Charlson 
Comorbidity Index 6) was vomiting and died of post-
operative pneumonia; the other (age 82 years, ASA class 3, 
Charlson comorbidity index 4) had extensive postoperative 
intra-abdominal bleeding, underwent two relaparotomies 
because of bleeding, and died from postoperative myocar-
dial infarction and stroke. The potential adverse effects of 
antibiotics (diarrhoea, Clostridium difficile infections, or 
allergic reactions) were similar between the two groups 
(table 3). Of the patients needing adjuvant therapy, 
60 (83%) of 72 patients in the MOABP group and 
74 (85%) of 87 in the NBP group actually received adjuvant 
therapy (table 3). We summarise adverse effects and 
Mechanical and oral 
antibiotic bowel 
preparation (n=196)
No bowel 
preparation 
(n=200)
No postoperative complications 103 (53%) 116 (58%)
Grade 1 complications (one or more per patient) 53 (27%) 54 (27%)
Superficial wound infection, wound dehiscence* 2 (1%) 6 (3%)
Ileus (vomiting, nasogastric tube placement) 37 (19%) 32 (16%)
Electrolyte imbalance 6 (3%) 6 (3%)
Collapse 3 (2%) 0
Urinary retention 3 (2%) 5 (3%)
Haematuria 1 (1%) 0
Urinary tract stone 1 (1%) 0
Diarrhoea 10 (5%) 11 (6%)
Incisional site bleeding 1 (1%) 1 (1%)
Bleeding ex ano, no need for any therapy 0 2 (1%)
Abnormal intensive incisional or operation site pain 2 (1%) 1 (1%)
Fever 0 2 (1%)
Thrombopenia 0 1 (1%)
Delirium 1 (1%) 0
Shortness of breath 1 (1%) 2
Headache 1 (1%) 0
Diuretics 1 (1%) 0
Grade 2 complications (one or more per patient) 47 (24%) 35 (18%)
Prolonged ileus with medication 8 (4%) 6 (3%)
Allergic reaction 0 1 (1%)
Fever with administrated antibiotics 10 (5%) 7 (4%)
Antibiotics administrated, reason not known 3 (2%) 3 (2%)
Pneumonia 5 (3%) 3 (2%)
Diarrhoea with Clostridium difficile 0 1 (1%)
Pulmonary embolism 3 (2%) 2 (1%)
Deep vein thrombosis 1 (1%) 0
Urinary tract infection 5 (3%) 0
Congestive heart failure worsening 2 (1%) 2 (1%)
Atrial fibrillation 4 (2%) 3 (2%)
Abscess 0 3 (2%)
Postoperative bleeding or anaemia, transfusion 9 (5%) 13 (7%)
Intraluminal haemorrhage, transfusion 1 (1%) 0
Incisional site pain, local anaesthetic injection 0 1 (1%)
Anastomotic dehiscence, class A, no intervention 0 1 (1%)
Ascites 0 1 (1%)
Candida spp infection 2 (1%) 0
Grade 3a complications (one or more per patient) 6 (3%) 3 (2%)
Intraluminal stricture, endoscopic treatment 1 (1%) 0
Intraluminal haemorrhage, endoscopic treatment 2 (1%) 0
Intra-abdominal abscess with percutaneous drainage 0 2 (1%)
Pleural effusion, pleural drainage 4 (2%) 1 (1%)
Ureteral lesion, catheter and irrigation 1 (1%) 0
Grade 3b (one or more per patient) 16 (8%) 10 (5%)
Anastomotic dehiscence, laparotomy 6 (3%) 5 (3%)
Abscess, postoperative peritonitis, laparotomy 2 (1%) 0
Intra-abdominal bleeding, laparotomy 2 (1%) 0
Intraluminal bleeding, endoscopy, general anaesthesia 1 (1%) 1 (1%)
Fascial dehiscence, resuture, general anaesthesia 4 (2%) 3 (2%)
(Table 4 continues on next page)
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complications in table 4. Almost half of the patients 
experienced a complication, of which most were minor 
(CD grade 1 or 2). The most common complication was 
ileus, which was treated conservatively.
Discussion
To our knowledge, this trial was the first prospective 
randomised trial comparing MOABP with NBP before 
elective colon resection. The development of SSI was 
similar in patients undergoing MOABP to those with 
NBP (13 [7%] of 196 vs 21 [11%] of 200). Cumulative 
postoperative complications, as measured by the highly 
sensitive CCI,30 did not indicate any difference in overall 
postoperative mor bidity. These results suggest that 
MOABP is ineffective in reducing SSIs or overall 
morbidity of colon surgery compared with NBP.
Several large retrospective series have reported that SSI 
occurs in 3·2–8·6% of patients undergoing MOABP and 
9·0–16·8% of patients receiving NBP.9–13,15,31 Most of these 
series used data from ASC NSQIP and probably consisted 
of (at least partially) the same patients.9–13,16,31 The absolute 
(percentage point) difference in SSIs between MOABP 
and NBP in these series have varied between 4·7% and 
10·0%. In most of these series, the laparoscopic approach 
was used in 61–71% of patients,10,11,31 which is slightly lower 
than our use of laparoscopic surgery (78%), and could 
affect the development of SSIs. A European prospective 
non-randomised multicentre cohort from the 2017 
European Society of Coloproctology32 collaborating group 
showed a lower risk of anastomotic leak in patients 
undergoing MOABP than in those receiving NBP. 
However, this cohort included only left-sided colectomies 
and included rectal resections. We found a 4% absolute 
difference between MOABP and NBP, but this difference 
was not statistically significant. Furthermore, the retro-
spective series reported a marked decrease in overall 
30-day morbidity in favour of MOABP.33,34 By contrast, our 
study did not show that MOABP decreased overall 
postoperative morbidity. These between-study differ-
ences are likely to be because of several biases in these 
retrospective series, as emphasised by Beyer-Berjot and 
Slim.35 Patients who did not undergo preoperative 
MOABP in these retrospective trials had more comor-
bidities10,13,31 and a more advanced stage of colorec tal cancer 
than those who had NBP.10,11,31 Patients were classified 
according to the type of preparation they were intended 
to receive, not what they actually received.10 The retro-
spective series did not report the use of preoperative 
prophylactic intravenous antibiotics or the types of oral 
antibiotics. Furthermore, sample sizes in these reports 
varied widely, although they consisted of patients from the 
same database from the same time period,11,13,31 which 
might indicate the presence of selective reporting. The 
differences might also be because of different scoring 
systems for postoperative complications. We used the 
most comprehensive and sensitive index, CCI, to obtain 
reliable data for post operative complications. This index 
considers all the cumulative complications instead of only 
recording the most severe one (which is usually the case 
when reporting complications using CD classification 
only).30 Furthermore, we did not find any differences in 
the proportion of patients who had reoperations, were 
readmitted to hospital, or died, and the length of hospital 
stay was similar between the groups. Considering these 
secondary outcomes and the potential disadvantage of 
the MOABP for the patient (discomfort involved in 
drinking large amounts of liquid, nausea, dehydration) a 
small decrease in the risk of developing a superficial SSI 
would not be worthwhile. Notably, adverse effects of 
antibiotics were similar between the groups, which 
might be because both groups received preoperative 
prophylactic intravenous antibiotics. Retrospective series 
have also reported similar,36 or an even lower prevalence 
of C difficile infection after MOABP.37 Although no other 
randomised controlled trial comparing MOABP with 
NPB exists, several randomised controlled trials show 
beneficial results for MOABP when compared with 
mechanical bowel preparation only.21–23 These results 
cannot be extrapolated directly to the NBP strategy, 
because mechanical bowel prepa ration could increase 
development of SSIs.24 The randomised controlled trials 
comparing MOABP with oral antibiotic prophylaxis 
found no difference in terms of SSI.20,38
This trial has some limitations. First, it was powered 
to detect an 8% absolute difference in SSIs. We found 
a 4% absolute difference in SSIs, which did not reach 
statistical significance. Thus, this trial was underpowered 
to detect such a small difference. From a clinical point of 
view and from a patient’s perspective, overall postope-
rative morbidity is more important than SSIs. Overall 
postoperative complications were similar and the 
compli cation index was slightly higher in the MOABP 
group than the NBP group. Second, this trial was not 
Mechanical and oral 
antibiotic bowel 
preparation (n=196)
No bowel 
preparation 
(n=200)
(Continued from previous page)
Ureter lesion, laparotomy 1 (1%) 0
Intestinal occlusion, laparotomy 1 (1%) 1 (1%)
Grade 4a complications 0 0
Grade 4b complications (one or more per patient) 1 (1%) 3 (2%)
Anastomotic dehiscence leading to multiple organ 
dysfunction and intensive care
1 (1%) 2 (1%)
Necrosis of bowel proximal to anastomotic site leading 
to multiple organ dysfunction and intensive care
0 1 (1%)
Grade 5 complications (death) 0 2 (1%)
Postoperative intra-abdominal bleeding, stroke 0 1 (1%)
Pneumonia 0 1 (1%)
*Only the most severe surgical site infection is reported in table 3, whereas all cumulative and multiple complications 
are reported in this table; for this reason, these values differ between the tables. Individual patients might have several 
complications reported.
Table 4: Cumulative postoperative complications within 30 days classified by use of Clavien-Dindo grade
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double-blinded, but because of the nature of the 
intervention, such blinding would have been impossible 
to imple ment. Patients will inevitably know whether 
they have undergone mechanical bowel preparation or 
not, even if placebo bowel preparation was introduced. 
However, we sought to keep the allocation group 
concealed from all the others by all possible means, and 
even the results were analysed without knowing the 
allocation group. Third, no prespecified subgroup 
analyses were planned for right versus left colectomies. 
Fourth, we used single doses of oral antibiotics the day 
before the surgery. The single doses were based on the 
protocols of earlier trials comparing MOABP to mecha-
nical bowel preparation,25,26 although some other trials 
divided the dose into several portions administrated 
within 1 day or several days.26,38 The different oral 
antibiotic regimens might influence the effectiveness of 
the antibiotics, but an earlier ran domised trial comparing 
a single dose with three doses did not show a difference 
in terms of reducing SSI, but a single dose was better 
tolerated by the patients than was three doses.26 Finally, 
the decision to use CT scans to detect anastomotic 
dehiscence was made on the basis of clinical signs 
and symptoms. No routine radiographic studies were 
included in the protocol to detect asymp tomatic anas-
tomotic leaks. However, we do not do imaging studies 
routinely in asymptomatic patients in our normal 
daily clinical practice, and clinical significance of such 
asymptomatic, but radiographic anastomotic leak after 
colon surgery is unclear.
This trial has several strengths. First, this was a 
multicentre trial including both university and non-
university hospitals, thus improving its external validity. 
Second, the patients were on average aged 70 years, and 
approximately 50% were patients at high-risk according 
to their ASA class 3–4, indicating that the case-mix 
accurately represents daily clinical practice. Finally, 
postoperative morbidity was meticulously recorded and 
reported by use of the most sensitive and accurate 
complication scoring system available.
To our knowledge, this is the first prospective, ran-
domised, controlled trial comparing MOABP with no 
preparation. Another trial (COLONPREP; NCT03475680) 
will be recruiting to compare MOABP with NBP using 
the same antibiotics, in colonic surgery.
In summary, our results suggest that MOABP does not 
reduce the occurrence of SSIs or overall morbidity after 
colonic surgery.
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